Updated Jul 16, 2026
Grund Nicholas is a corporate insider tracked by InsiderAlpha. No SEC Form 4 filings recorded in the last 90 days. Lifetime open-market sales: $118K.
Nicholas Grund is associated with Akebia Therapeutics, Inc., a biopharmaceutical company focused on developing therapies for kidney disease. Specific details about his role and contributions to the company are not widely documented.
| Role | Insider |
|---|---|
| Notability | 10/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-02-04 | AKBA | Akebia Therapeutics, Inc. | S — Open-market sale [10b5-1] | 31.2K | $1.39 | $43K |
| 2026-02-04 | AKBA | Akebia Therapeutics, Inc. | S — Open-market sale [10b5-1] | 53.6K | $1.39 | $74K |
| 2026-02-03 | AKBA | Akebia Therapeutics, Inc. | A — Grant or award | 204.0K | $0.00 |
Nicholas Grund is associated with Akebia Therapeutics, Inc., a biopharmaceutical company focused on developing therapies for kidney disease. Specific details about his role and contributions to the company are not widely documented.…
Recorded transactions: 0 open-market purchases () and 2 open-market sales ($118K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Grund Nicholas profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.